Back to search

Article

Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer

2023-05-30

Abstract excerpt

<title>Abstract</title> <p>Purpose Here, we investigated the potential predictive and elucidating efficacy of cell-free DNA (cfDNA) changes on clinical outcomes and biological effects, respectively, after short-term palbociclib and fulvestrant treatment for patients with hormone receptor (HR)-positive and human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer (ABC). Methods In this...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
658812e0-0cb9-5606-a170-51505b679315
DOI
10.21203/rs.3.rs-2909789/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancerDOI 10.21203/rs.3.rs-2909789/v1
Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.Semantic proximity
Exploring Mechanism of Action of Abemaciclib in Breast Cancer Through Circulating Chromatin FragmentSemantic proximity
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.Semantic proximity
Cell-Free DNA: Hope and Potential Application in CancerSemantic proximity
Dynamic Monitoring and Identification of Reliable Biomarkers to Predict Efficacy of Bireociclib and Fulvestrant: An Exploratory ctDNA Analysis of the BRIGHT-2 StudySemantic proximity
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerSemantic proximity
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.Semantic proximity
Use of cell free DNA in breast oncology.Semantic proximity
Cell-Free DNA Variables including Gene Mutations in CA15-3 Normal Breast Cancer Reflect Prognosis.Semantic proximity
Cell-free DNA comparative analysis of genomic landscape of first-line hormone-receptor positive metastatic breast cancer from US and ChinaSemantic proximity
Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.Semantic proximity
Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLCSemantic proximity
Select a neighboring publication to make it the new centre.